Erratum: Sequential local injection of low-dose interferon-beta for maintenance therapy in stage II and III melanoma: A single-institution matched case-control study (Oncology (Switzerland) (2012) 82 (139-146) DOI: 10.1159/000336490);Sequential local injection of low-dose interferon-beta for maintenance therapy in stage II and III melanoma: A single-institution matched case-control study

Oncology

Volumn 82, Issue 3, 2012, Pages 139-146

  Aoyagi, Satoru ^a   Hata, Hiroo ^a   Homma, Erina ^a   Shimizu, Hiroshi ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adjuvant therapy; Case control study; Immunotherapy; Interferon; Melanoma; Therapeutic efficacy

Indexed keywords

RECOMBINANT BETA INTERFERON;

ADULT; ANEMIA; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CASE CONTROL STUDY; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG FEVER; FATIGUE; FEMALE; HUMAN; INJECTION SITE ERYTHEMA; LIVER DYSFUNCTION; LOW DRUG DOSE; MAINTENANCE THERAPY; MALE; MELANOMA; NEUTROPENIA; OVERALL SURVIVAL; PRIMARY CUTANEOUS MELANOMA; PRIMARY TUMOR; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVIEW; SKIN CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; VITILIGO;

EID: 84858320765     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000339520     Document Type: Erratum

References (26)

1. Schmid-Wendtner MH, Baumert J, Eberle J, Plewig G, Volkenandt M, Sander CA: Disease progression in patients with thin cutaneous melanomas (tumour thickness ! or = 0.75 mm): clinical and epidemiological data from the Tumour Center Munich 1977-98. Br J Dermatol 2003; 149: 788-793. (Pubitemid 37412000)
2. Slingluff CL Jr, Dodge RK, Stanley WE, Seigler HF: The annual risk of melanoma progression. Implications for the concept of cure. Cancer 1992; 70: 1917-1927.
3. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM: Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011; 16: 5-24.
4. Eggermont AM, Testori A, Marsden J, Hersey P, Quirt I, Petrella T, Gogas H, Mac-Kie RM, Hauschild A: Utility of adjuvant systemic therapy in melanoma. Ann Oncol 2009; 20(suppl 6):S30-S34.
5. Ishihara K, Hayasaka K, Yamazaki N: Current status of melanoma treatment with interferon, cytokines and other biologic response modifiers in Japan. J Invest Dermatol 1989; 92(suppl 5):S326-S328.
6. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S: Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003; 29: 241-252. (Pubitemid 37069655)
7. Pirard D, Heenen M, Melot C, Vereecken P: Interferon alpha as adjuvant postsurgical treatment of melanoma: a meta-analysis. Dermatology 2004; 208: 43-48. (Pubitemid 38142333)
8. Kefford RF: Adjuvant therapy of cutaneous melanoma: the interferon debate. Ann Oncol 2003; 14: 358-365. (Pubitemid 36367410)
9. Mao L, Si L, Chi Z, Cui C, Sheng X, Li S, Tang B, Guo J: A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon-2b in high-risk acral melanoma patients. Eur J Cancer 2011; 47: 1498-1503.
10. Mocellin S, Pasquali S, Rossi CR, Nitti D: Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010; 102: 493-501.
11. Horikoshi T, Fukuzawa K, Hanada N, Ezoe K, Eguchi H, Hamaoka S, Tsujiya H, Tsukamoto T: In vitro comparative study of the antitumor effects of human interferon-alpha, beta and gamma on the growth and invasive potential of human melanoma cells. J Dermatol 1995; 22: 631-636.
12. Johns TG, Mackay IR, Callister KA, Hertzog PJ, Devenish RJ, Linnane AW: Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon beta. J Natl Cancer Inst 1992; 84: 1185-1190.
13. Kubo H, Ashida A, Matsumoto K, Kageshita T, Yamamoto A, Saida T: Interferon-beta therapy for malignant melanoma: the dose is crucial for inhibition of proliferation and induction of apoptosis of melanoma cells. Arch Dermatol Res 2008; 300: 297-301.
14. Borden EC, Hogan TF, Voelkel JG: Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells. Cancer Res 1982; 42: 4948-4953. (Pubitemid 13223128)
15. Chawla-Sarkar M, Leaman DW, Borden EC: Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res 2001; 7: 1821-1831. (Pubitemid 32708654)
16. Chawla-Sarkar M, Leaman DW, Jacobs BS, Borden EC: IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis. J Immunol 2002; 169: 847-855. (Pubitemid 34753441)
17. Gomi K, Morimoto M, Nakamizo N: Antitumor effect of human recombinant interferon-beta against human melanomas transplanted into nude mice. J Pharmacobiodyn 1984; 7: 951-961. (Pubitemid 15174853)
18. Fujimura T, Okuyama R, Ohtani T, Ito Y, Haga T, Hashimoto A, Aiba S: Perilesional treatment of metastatic melanoma with interferon-beta. Clin Exp Dermatol 2009; 34: 793-799.
19. Borden EC, Jacobs B, Hollovary E, Rybicki L, Elson P, Olencki T, Triozzi P: Gene regulatory and clinical effects of interferon-in patients with metastatic melanoma: a phase II trial. J Interferon Cytokine Res 2011; 31: 433-440.
20. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, Parulekar W, Markovic SN, Saxman S, Kirkwood JM: Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008; 26: 527-534. (Pubitemid 351264344)
21. Nagatani T, Ichiyama S, Onuma R, Miyazawa M, Matsuzaki T, Miyagawa K, Baba N, Uchiyama M, Nakajima H: The use of DAV (DTIC, ACNU and VCR) and natural interferon-beta combination therapy in malignant melanoma. Acta Derm Venereol 1995; 75: 494. (Pubitemid 26051894)
22. Matsumoto K, Kubo H, Murata H, Uhara H, Takata M, Shibata S, Yasue S, Sakakibara A, Tomita Y, Kageshita T, Kawakami Y, Mizuno M, Yoshida J, Saida T: A pilot study of human interferon beta gene therapy for patients with advanced melanoma by in vivo transduction using cationic liposomes. Jpn J Clin Oncol 2008; 38: 849-856.
23. Ishihara K, Saida T, Otsuka F, Yamazaki N: Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. Int J Clin Oncol 2008; 13: 33-41. (Pubitemid 351326291)
24. Boasberg PD, Hoon DS, Piro LD, Martin MA, Fujimoto A, Kristedja TS, Bhachu S, Ye X, Deck RR, O'Day SJ: Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol 2006; 126: 2658-2663. (Pubitemid 44764050)
25. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM: Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354: 709-718. (Pubitemid 43247141)
26. Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, Punt CJ, Delauney M, Sales F, Groenewegen G, Ruiter DJ, Jagiello I, Stoitchkov K, Keilholz U, Lienard D, EORTC Melanoma Group: Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005; 366: 1189-1196. (Pubitemid 41393597)